{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:56:27Z","timestamp":1792716987321,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>This study evaluates the real-world eligibility of patients with early Alzheimer's disease (AD) for donanemab, a monoclonal antibody targeting amyloid plaques. At a tertiary center in Italy, 408 patients with mild cognitive impairment (MCI) or mild AD were assessed against clinical trial criteria. While 41% were amyloid-positive, only 10.05% met eligibility for treatment, primarily due to exclusions for amyloid biomarkers, medical conditions, and MRI findings. These results highlight the gap between trial populations and real-world patients. Balancing efficacy with safety remains a key challenge in expanding access to anti-AD immunotherapy like donanemab in routine clinical practice.<\/jats:p>","DOI":"10.1177\/13872877251331243","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:09:49Z","timestamp":1746173389000},"page":"745-750","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Donanemab eligibility in early Alzheimer's disease: A real-world study"],"prefix":"10.1177","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-0110","authenticated-orcid":false,"given":"Daniele","family":"Urso","sequence":"first","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-6442","authenticated-orcid":false,"given":"Alessandro","family":"Introna","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gnoni","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Giugno","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Vilella","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Blasi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, \u201cPia Fondazione Cardinale G. Panico\u201d, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Giannoni-Luza","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-3242","authenticated-orcid":false,"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari \u2018Aldo Moro\u2019, Tricase, Italy"},{"name":"Department of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02087-4"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","unstructured":"Espay AJ Kepp KP Herrup K. Lecanemab and donanemab as therapies for Alzheimer's disease: an illustrated perspective on the data. eNeuro 2024; 11: ENEURO.0319\u201323.","DOI":"10.1523\/ENEURO.0319-23.2024"},{"key":"e_1_3_5_6_2","unstructured":"U. S. C. Schaeffer Center for Health Policy Economics. Key Barriers for Clinical Trials for Alzheimer\u2019s Disease https:\/\/healthpolicy.usc.edu\/research\/key-barriers-for-clinical-trials-for-alzheimers-disease\/ 2024."},{"key":"e_1_3_5_7_2","article-title":"Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab","volume":"32","author":"Logroscino G","year":"2024","unstructured":"Logroscino G, Urso D, Gnoni V, et al. Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab. Eur J Neurol 2024; 32: e16534.","journal-title":"Eur J Neurol"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17530"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00131-X"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018170803"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70013-4"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.07.004"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad159"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073892"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae216"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26913"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915050-00001"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004241"},{"key":"e_1_3_5_24_2","unstructured":"Leqembi recommended for treatment of early Alzheimer\u2019s disease. European Medicines Agency 2024."}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251331243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251331243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251331243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:10:22Z","timestamp":1777371022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251331243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/13872877251331243"],"URL":"https:\/\/doi.org\/10.1177\/13872877251331243","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}